5FCR

MOUSE COMPLEMENT FACTOR D


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.25 Å
  • R-Value Free: 0.196 
  • R-Value Work: 0.150 
  • R-Value Observed: 0.152 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Small-molecule factor D inhibitors targeting the alternative complement pathway.

Maibaum, J.Liao, S.M.Vulpetti, A.Ostermann, N.Randl, S.Rudisser, S.Lorthiois, E.Erbel, P.Kinzel, B.Kolb, F.A.Barbieri, S.Wagner, J.Durand, C.Fettis, K.Dussauge, S.Hughes, N.Delgado, O.Hommel, U.Gould, T.Mac Sweeney, A.Gerhartz, B.Cumin, F.Flohr, S.Schubart, A.Jaffee, B.Harrison, R.Risitano, A.M.Eder, J.Anderson, K.

(2016) Nat Chem Biol 12: 1105-1110

  • DOI: 10.1038/nchembio.2208
  • Primary Citation of Related Structures:  
    5FCR, 5FAH, 5FBI, 5FBE, 5FCK

  • PubMed Abstract: 
  • Complement is a key component of the innate immune system, recognizing pathogens and promoting their elimination. Complement component 3 (C3) is the central component of the system. Activation of C3 can be initiated by three distinct routes-the classical, the lectin and the alternative pathways-with the alternative pathway also acting as an amplification loop for the other two pathways ...

    Complement is a key component of the innate immune system, recognizing pathogens and promoting their elimination. Complement component 3 (C3) is the central component of the system. Activation of C3 can be initiated by three distinct routes-the classical, the lectin and the alternative pathways-with the alternative pathway also acting as an amplification loop for the other two pathways. The protease factor D (FD) is essential for this amplification process, which, when dysregulated, predisposes individuals to diverse disorders including age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH). Here we describe the identification of potent and selective small-molecule inhibitors of FD. These inhibitors efficiently block alternative pathway (AP) activation and prevent both C3 deposition onto, and lysis of, PNH erythrocytes. Their oral administration inhibited lipopolysaccharide-induced AP activation in FD-humanized mice. These data demonstrate the feasibility of inhibiting the AP with small-molecule antagonists and support the development of FD inhibitors for the treatment of complement-mediated diseases.


    Organizational Affiliation

    Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Complement factor DA, B, C, D234Mus musculusMutation(s): 0 
Gene Names: CfdAdnDf
EC: 3.4.21.46
UniProt & NIH Common Fund Data Resources
Find proteins for P03953 (Mus musculus)
Explore P03953 
Go to UniProtKB:  P03953
IMPC:  MGI:87931
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 4 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
EPE
Query on EPE

Download Ideal Coordinates CCD File 
E [auth B], G [auth C]4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID
C8 H18 N2 O4 S
JKMHFZQWWAIEOD-UHFFFAOYSA-N
 Ligand Interaction
SO4
Query on SO4

Download Ideal Coordinates CCD File 
H [auth C]SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
GOL
Query on GOL

Download Ideal Coordinates CCD File 
F [auth B]GLYCEROL
C3 H8 O3
PEDCQBHIVMGVHV-UHFFFAOYSA-N
 Ligand Interaction
DMS
Query on DMS

Download Ideal Coordinates CCD File 
I [auth D], J [auth D]DIMETHYL SULFOXIDE
C2 H6 O S
IAZDPXIOMUYVGZ-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.25 Å
  • R-Value Free: 0.196 
  • R-Value Work: 0.150 
  • R-Value Observed: 0.152 
  • Space Group: P 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 51.271α = 90.46
b = 52.866β = 98.04
c = 84.278γ = 90.14
Software Package:
Software NamePurpose
REFMACrefinement
XDSdata reduction
XSCALEdata scaling
MOLREPphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Deposited Date: 2015-12-15 
  • Released Date: 2016-10-26 
  • Deposition Author(s): Mac Sweeney, A.

Revision History  (Full details and data files)

  • Version 1.0: 2016-10-26
    Type: Initial release
  • Version 1.1: 2016-11-02
    Changes: Database references
  • Version 1.2: 2016-11-23
    Changes: Database references